124I-Evuzamitide for Spinal Stenosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial will use the amyloid-binding radiotracer, 124I-evuzamitide, to potentially detect amyloid, in the heart and elsewhere, in patients who have a history of lumbar spinal stenosis and/or carpal tunnel syndrome.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking heparin or heparin derivatives (blood thinners).
How does the drug 124I-evuzamitide differ from other treatments for spinal stenosis?
Who Is on the Research Team?
Emily B. Martin, PhD
Principal Investigator
University of Tennessee Graduate School of Medicine
Are You a Good Fit for This Trial?
This trial is for patients with a history of lumbar spinal stenosis and/or carpal tunnel syndrome. It aims to detect amyloid deposits in the heart and other areas using a special imaging agent.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are administered 124I-evuzamitide and undergo PET/CT imaging to detect cardiac and extracardiac amyloid
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- 124I-evuzamitide
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Tennessee Graduate School of Medicine
Lead Sponsor
Attralus, Inc.
Industry Sponsor